CN102690270A - 嘧啶类化合物及其用途 - Google Patents
嘧啶类化合物及其用途 Download PDFInfo
- Publication number
- CN102690270A CN102690270A CN201210167798XA CN201210167798A CN102690270A CN 102690270 A CN102690270 A CN 102690270A CN 201210167798X A CN201210167798X A CN 201210167798XA CN 201210167798 A CN201210167798 A CN 201210167798A CN 102690270 A CN102690270 A CN 102690270A
- Authority
- CN
- China
- Prior art keywords
- human
- methyl
- compound
- cancer
- boc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 Pyrimidine compound Chemical class 0.000 title claims abstract description 9
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 8
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 8
- 201000007270 liver cancer Diseases 0.000 claims abstract description 8
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 5
- 201000005202 lung cancer Diseases 0.000 claims abstract description 5
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 5
- 150000003230 pyrimidines Chemical class 0.000 claims description 7
- APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical class N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 201000008275 breast carcinoma Diseases 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 14
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000003810 ethyl acetate extraction Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 201000005296 lung carcinoma Diseases 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 1
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- IMXHGCRIEAKIBU-UHFFFAOYSA-N 4-[6-[4-(methoxycarbonylamino)phenyl]-4-(4-morpholinyl)-1-pyrazolo[3,4-d]pyrimidinyl]-1-piperidinecarboxylic acid methyl ester Chemical compound C1=CC(NC(=O)OC)=CC=C1C1=NC(N2CCOCC2)=C(C=NN2C3CCN(CC3)C(=O)OC)C2=N1 IMXHGCRIEAKIBU-UHFFFAOYSA-N 0.000 description 1
- KGMUNIJATLESGL-UHFFFAOYSA-N CC1=CC=C(C(=O)OCBr)C=C1 Chemical class CC1=CC=C(C(=O)OCBr)C=C1 KGMUNIJATLESGL-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical compound C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
- 238000003805 vibration mixing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
编号 | 人乳腺癌细胞 | 人肺癌细胞 | 人肝癌细胞 | 人结肠癌细胞 |
7a | ++++ | ++++ | ++++ | ++++ |
7b | +++ | ++ | +++ | ++ |
7c | ++++ | ++++ | +++ | ++++ |
7d | +++ | +++ | +++ | ++ |
7e | ++ | +++ | ++ | ++ |
7f | +++ | +++ | +++ | ++ |
7g | ++ | +++ | ++ | ++ |
7h | ++ | + | ++ | ++ |
7i | ++++ | ++++ | ++++ | ++++ |
7j | +++ | +++ | ++ | ++ |
7k | +++ | ++++ | +++ | +++ |
7l | ++++ | ++++ | +++ | ++++ |
7m | +++ | +++ | +++ | ++ |
7n | ++++ | ++++ | ++++ | +++ |
7o | ++ | +++ | +++ | +++ |
7p | +++ | +++ | ++ | +++ |
7q | +++ | ++ | ++ | ++ |
7r | +++ | ++ | ++ | +++ |
7s | +++ | +++ | ++ | ++ |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210167798.XA CN102690270B (zh) | 2012-05-28 | 2012-05-28 | 嘧啶类化合物及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210167798.XA CN102690270B (zh) | 2012-05-28 | 2012-05-28 | 嘧啶类化合物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102690270A true CN102690270A (zh) | 2012-09-26 |
CN102690270B CN102690270B (zh) | 2014-02-05 |
Family
ID=46856021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210167798.XA Expired - Fee Related CN102690270B (zh) | 2012-05-28 | 2012-05-28 | 嘧啶类化合物及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102690270B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102977038A (zh) * | 2012-11-28 | 2013-03-20 | 河南大学 | 二(2-乙酰吡嗪基)硫代缩二氨基脲及其铋(iii)配合物的制备方法和应用 |
CN103242321A (zh) * | 2013-05-21 | 2013-08-14 | 苏州科捷生物医药有限公司 | 苄基哌嗪类化合物及其抗肿瘤用途 |
CN104072499A (zh) * | 2013-03-29 | 2014-10-01 | 黄传满 | 哌嗪取代嘧啶类化合物及其用途 |
CN104098574A (zh) * | 2013-04-12 | 2014-10-15 | 苏州科捷生物医药有限公司 | 氮杂环丁烷取代嘧啶类化合物及其用途 |
CN104119343A (zh) * | 2013-04-25 | 2014-10-29 | 苏州科捷生物医药有限公司 | 2-三氟甲基噻二唑类化合物及其用途 |
CN110548032A (zh) * | 2019-08-07 | 2019-12-10 | 四川大学华西医院 | 一种吡唑并嘧啶类化合物在制备预防/治疗肿瘤药物上的用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050277655A1 (en) * | 2004-06-09 | 2005-12-15 | Qingjie Ding | Pyrazolopyrimidines |
CN101054380A (zh) * | 2006-04-13 | 2007-10-17 | 沈阳药科大学 | 用作细胞周期依赖性蛋白激酶抑制剂的吡唑并嘧啶类衍生物 |
-
2012
- 2012-05-28 CN CN201210167798.XA patent/CN102690270B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050277655A1 (en) * | 2004-06-09 | 2005-12-15 | Qingjie Ding | Pyrazolopyrimidines |
CN101054380A (zh) * | 2006-04-13 | 2007-10-17 | 沈阳药科大学 | 用作细胞周期依赖性蛋白激酶抑制剂的吡唑并嘧啶类衍生物 |
Non-Patent Citations (2)
Title |
---|
ALESSANDRO ANTONELLI ET AL.: "Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activity in Vitro and in Vivo in Papillary Dedifferentiated Thyroid Cancer", 《JCEM ONLINE》, vol. 96, no. 2, 28 February 2011 (2011-02-28), pages 288 - 296 * |
陆涛 等: "吡唑并嘧啶衍生物的合成及其生物活性研究", 《江西师范大学学报(自然科学版)》, vol. 35, no. 1, 31 January 2011 (2011-01-31), pages 10 - 14 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102977038A (zh) * | 2012-11-28 | 2013-03-20 | 河南大学 | 二(2-乙酰吡嗪基)硫代缩二氨基脲及其铋(iii)配合物的制备方法和应用 |
CN102977038B (zh) * | 2012-11-28 | 2014-09-24 | 河南大学 | 二(2-乙酰吡嗪基)硫代缩二氨基脲及其铋(iii)配合物的制备方法和应用 |
CN104072499A (zh) * | 2013-03-29 | 2014-10-01 | 黄传满 | 哌嗪取代嘧啶类化合物及其用途 |
CN104098574A (zh) * | 2013-04-12 | 2014-10-15 | 苏州科捷生物医药有限公司 | 氮杂环丁烷取代嘧啶类化合物及其用途 |
CN104119343A (zh) * | 2013-04-25 | 2014-10-29 | 苏州科捷生物医药有限公司 | 2-三氟甲基噻二唑类化合物及其用途 |
CN103242321A (zh) * | 2013-05-21 | 2013-08-14 | 苏州科捷生物医药有限公司 | 苄基哌嗪类化合物及其抗肿瘤用途 |
CN110548032A (zh) * | 2019-08-07 | 2019-12-10 | 四川大学华西医院 | 一种吡唑并嘧啶类化合物在制备预防/治疗肿瘤药物上的用途 |
Also Published As
Publication number | Publication date |
---|---|
CN102690270B (zh) | 2014-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102690270B (zh) | 嘧啶类化合物及其用途 | |
Moafi et al. | New HA 14-1 analogues: synthesis of 2-amino-4-cyano-4H-chromenes | |
CN111393483B (zh) | 一种四价铂萘酰亚胺配合物、其制备方法及应用 | |
CN111377975B (zh) | 一种新的靶向线粒体的铱配合物及其制备方法和应用 | |
CN110066241A (zh) | 一种锌的Schiff碱配合物及其制备方法和应用 | |
CN103739549B (zh) | 一种萘酰亚胺-氨基酸化合物及其修饰的量子点的制备、应用 | |
CN103288684A (zh) | 一种具有抗肿瘤活性的联苯脲化合物及其制备方法 | |
CN102627685B (zh) | 一氧化氮供体型谷胱甘肽类化合物、其制备方法及医药用途 | |
CN104327156A (zh) | 二氢卟吩类光、声敏剂及其制备方法与应用 | |
CN102250149A (zh) | 一类弱配位键的离子型铱配合物及其制备方法和应用 | |
CN108395429A (zh) | 一种化合物及其制备方法和用途 | |
CN103360423B (zh) | 一苄基锡芳香醛缩芳胺Schiff碱配合物及制备方法与应用 | |
CN111393482B (zh) | 一种铂-铱异核金属配合物及其制备方法和应用 | |
CN103408597A (zh) | 一种芳烃钌配合物及其合成方法 | |
Zhang et al. | Design, synthesis, antitumor activity and ct-DNA binding study of photosensitive drugs based on porphyrin framework | |
CN103435554A (zh) | 2-苯氨基苯并咪唑类化合物及其用途 | |
CN103435560A (zh) | 一类带柔性侧链的苊并[1,2-b]喹喔啉衍生物的合成及其应用 | |
CN104177346A (zh) | 喹唑啉类化合物及其用途 | |
CN102276433A (zh) | 木豆素c及其衍生物及其在制备抗癌药物中的应用 | |
CN103242321A (zh) | 苄基哌嗪类化合物及其抗肿瘤用途 | |
CN114773361B (zh) | N-杂尼罗红鎓盐类化合物及其制备方法和应用 | |
CN102491934B (zh) | 羟基苯甲醛吲哚席夫碱及其制备方法和应用 | |
CN103554116B (zh) | 一种分子靶向抗癌光敏剂他莫昔芬-酞菁轭合物及其制备方法 | |
CN104341407A (zh) | 喹唑啉类化合物及其制备方法和用途 | |
CN104961794B (zh) | 一种丹参酮iia衍生物及其制备和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SUZHOU KEJIE BIOLOGICAL MEDICINE CO., LTD. Free format text: FORMER OWNER: WU YAN Effective date: 20130423 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Huang Chuanman Inventor after: Jie Meina Inventor after: Wu Yan Inventor before: Wu Yan |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WU YAN TO: HUANG CHUANMAN JIE MEINA WU YAN Free format text: CORRECT: ADDRESS; FROM: 215100 SUZHOU, JIANGSU PROVINCE TO: 215123 SUZHOU, JIANGSU PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20130423 Address after: Xinghu Street Industrial Park of Suzhou city in Jiangsu province 215123 No. 218 building A3 room 312 Applicant after: Kejie-Bio (Suzhou) Pharmaceutical Co., Ltd. Address before: Suzhou City, Jiangsu Province, Suzhou Industrial Park 215100 Xinghu Street No. 218 building A3 room 312 Applicant before: Wu Yan |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140205 Termination date: 20200528 |